CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

As the DeepSeek craze ignites a sell-off in the tech sector, investors are weighing the implications of the downturn in the ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

The global Continuous Thermal Monitoring Market is anticipated to grow from estimated USD 1.00 billion in 2024 to USD 1.49 billion by 2030, at a CAGR of 6.8% during the forecast period. The market is ...